- Home
- ADT vs CYTK Comparison
ADT vs CYTK Comparison
Compare ADT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADT
- CYTK
- Stock Information
- Founded
- ADT 1874
- CYTK 1997
- Country
- ADT United States
- CYTK United States
- Employees
- ADT N/A
- CYTK N/A
- Industry
- ADT Diversified Commercial Services
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- ADT Consumer Discretionary
- CYTK Health Care
- Exchange
- ADT Nasdaq
- CYTK Nasdaq
- Market Cap
- ADT 6.8B
- CYTK 5.6B
- IPO Year
- ADT 2018
- CYTK 2004
- Fundamental
- Price
- ADT $8.16
- CYTK $32.43
- Analyst Decision
- ADT Buy
- CYTK Buy
- Analyst Count
- ADT 4
- CYTK 14
- Target Price
- ADT $9.05
- CYTK $70.92
- AVG Volume (30 Days)
- ADT 19.4M
- CYTK 1.3M
- Earning Date
- ADT 07-31-2025
- CYTK 08-07-2025
- Dividend Yield
- ADT 2.70%
- CYTK N/A
- EPS Growth
- ADT N/A
- CYTK N/A
- EPS
- ADT 0.59
- CYTK N/A
- Revenue
- ADT $4,976,265,000.00
- CYTK $19,218,000.00
- Revenue This Year
- ADT $5.95
- CYTK $18.02
- Revenue Next Year
- ADT $4.34
- CYTK $737.32
- P/E Ratio
- ADT $13.78
- CYTK N/A
- Revenue Growth
- ADT 5.65
- CYTK 412.21
- 52 Week Low
- ADT $6.53
- CYTK $29.31
- 52 Week High
- ADT $8.72
- CYTK $61.38
- Technical
- Relative Strength Index (RSI)
- ADT 46.42
- CYTK 46.32
- Support Level
- ADT $8.02
- CYTK $32.02
- Resistance Level
- ADT $8.25
- CYTK $34.72
- Average True Range (ATR)
- ADT 0.21
- CYTK 1.30
- MACD
- ADT -0.04
- CYTK 0.26
- Stochastic Oscillator
- ADT 20.00
- CYTK 45.08
About ADT ADT Inc.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name. The company segments include Consumer and Small Business (CSB).
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.